Halda Therapeutics
Amit Bhardwaj has a diverse work experience in the field of research and biotechnology. Starting in 2001, they worked as a Research Associate at ICGEB until 2005. Amit then went on to pursue their PhD, focusing on the study of a thermostable family 10 xylanase. During their PhD, they utilized biochemical, biophysical, and proteomic approaches to understand the role of N- and C-terminal aromatic cluster interaction in GH10 xylanase protein stability and folding. After completing their PhD in 2010, Amit joined ICGEB as a Post Doctoral Fellow. Amit'sresearch revolved around studying the molecular basis of TDP-RNA interactions and their involvement in RNA processing. In 2014, they moved to NYU Langone Health, where they initially worked as a Postdoctoral Researcher, contributing significantly to the field of tankyrase research. Amit'sachievements include designing and performing a quantitative proteomic screen to identify the role of tankyrase and developing the first-ever human tankyrase knockout cell lines using CRISPR-Cas9. Amit was also involved in successful collaborations and published their work within the timeframe. Finally, in 2021, they joined Halda Therapeutics as a Senior Research Scientist, where they currently work.
Amit Bhardwaj completed their education from 2005 to 2010 at Delhi University, where they obtained a PhD in Biochemistry and Molecular Biology.
This person is not in any offices
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.